ArticleOncology letters2026
A cross-platform transcriptomic risk score integrating LymphoMAP microenvironment archetypes and immune evasion-associated programs in diffuse large B-cell lymphoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is clinically heterogeneous and existing prognostic indices incompletely capture its biological diversity. The present study aimed to investigate how transcriptome-inferred LymphoMAP archetypes (lymph node-like, fibroblast-macrophage-rich and T cell-exhausted) relate to genetic subtypes and immune evasion-associated programs, and whether integrating these dimensions improves risk stratification beyond the International Prognostic Index (IPI). Using the DLBCL-2018 cohort (n=562), LymphoMAP archetypes were inferred and immune programs were quantified by single-sample gene set enrichment analysis, summarizing them into an immune evasion-associated index. In the immunochemotherapy-treated subset (n=234), overall survival was assessed and an elastic-net Cox model was developed to derive a transcriptomic risk score (RScore-Expr). The score was externally evaluated in four independent Gene Expression Omnibus cohorts (n=1,173) with a random-effects meta-analysis performed across studies. LymphoMAP archetypes were non-randomly associated with genetic subtypes (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.